Menu

Members of Presidential Advisory Council on HIV/AIDS Fired

The move follows mass resignations from the council in June. 

Jan 3, 2018
Katarina Zimmer

LGBT solidarity rally in February 2017 FLICKR, MATHIASWASIKLast week, President Donald Trump's administration dismissed the remaining members of the Presidential Advisory Council on HIV/AIDS (PACHA). This follows the mass resignation of half of the members of the council in June, in protest of the administration’s position on health policy.

The 10 remaining members of PACHA, who were appointed under former President Barack Obama's administration, received letters last Wednesday (December 27) “informing them that the administration was terminating their appointments,” PACHA’s executive director Kaye Hayes says in a statement (via The Washington Post).

PACHA was instituted in 1995 to make recommendations to the White House and the Secretary of Health and Human Services about ways to promote the treatment and prevention of HIV and AIDS. It is intended to include “doctors, members of industry, members of the community, and, very importantly, people living with HIV,” Scott Schoettes, a lawyer with Lambda Legal, a civil rights organization focusing on LGBT communities, and a former member of the council, tells The Washington Post. “Without it, you lose the community voice in policymaking.”

Schoettes was among those council members who had resigned in June, the “tipping point” for him being the President's aim to repeal the Obama-era Affordable Care Act (ACA). The ACA had been “of great importance for people living with HIV like myself,” he tells The Washington Post.  

The dismissals are part of a routine changing of federal advisory committee members, a “common occurrence during administration changes,” according to Hayes’s statement. She also notes that all members are allowed to reapply to serve on the council in 2018. However, some council members question the motives behind the unprecedented terminations.

Patrick Sullivan, an Emory University epidemiologist and one of the recently dismissed council members, tells The Washington Post that past administrations have usually allowed advisory council members to complete their terms before hiring replacements. “It is important to have a rolling, transitioning body that crosses administrations that really has a set of diverse outlooks on the epidemic,” he adds.

Although President Trump has previously affirmed his administration’s commitments to addressing the HIV and AIDS epidemic (such as in a speech on World AIDS Day), gay rights advocates say he has been discriminatory on a subtle level by erasing mentions of LGBT communities from his statements, according to ABC News.

“Trump has made a continuous effort to erase LGBTQ people and people living with HIV from the fabric of our country—actions that fly in the face of American values and that all fair-minded Americans will continue to push back against,” Sarah Kate Ellis, president of GLAAD, an LGBT rights advocacy group, tweeted last week.

Nicholas Carlisle, the executive director of the Southern AIDS Coalition who was dismissed from the council last week, tells ABC News that he is disappointed about the “unceremonious” termination. “But HIV is a bipartisan issue and we want to work with this administration just like we worked with the last administration and we wish the future PACHA members well,” he adds.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.